SAN DIEGO, Sept. 12, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced that the Company will provide an update on the DIFICID™ (fidaxomicin) tablets launch at the Morgan Stanley Global Healthcare Conference taking place in New York City. Pedro Lichtinger, Optimer's President and CEO, will comment on the DIFICID launch tomorrow, September 13, during a webcasted fireside chat at 8:00 AM ET. DIFICID was approved by the U.S. Food and Drug Administration in May of 2011 for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults 18 years of age and older. CDAD is a significant medical problem in hospitals and long-term care facilities, and DIFICID is the first antibacterial drug approved for the treatment of CDAD in 25 years.
"We believe the Optimer strategy is proving highly impactful, with DIFICID sales exceeding published analyst expectations in the initial stages of the launch. While early in the launch, we view it as a major success to date. We are committed to maintaining this momentum as the launch matures," said Pedro Lichtinger, president and CEO of Optimer Pharmaceuticals. "The growing evidence of the value of DIFICID to patients, hospitals and payers is being well received by practitioners and other stakeholders. Supported by DIFICID's clinical strength and value proposition, we believe the combined Optimer/Cubist field presence is having a material impact on accelerating prescriptions and formulary adoption."
There are several key components comprising the DIFICID launch effort and Optimer plans to review progress to date for each of those components.
1. DIFICID Sales
For the period of July 19, the date of DIFICID's first sales, through September 2 , Optimer estimates DIFICID gross sales of $
|SOURCE Optimer Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved